Todos Medical announces “Test & Tollovid®” vacation package

New York, NY, and Tel Aviv, ISRAELL, December 17, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA / CAP certified lab has launched the “Test & Tollovid®” vacation package for the Atlanta area. Vacation package is priced at $ 329 and includes one (1) bottle of maximum strength Tollovid and one (1) at-home saliva sample collection kit to return in a prepaid FedEx overnight envelope for a COVID PCR test -19. For faster test results, customers can drop off samples at the lab during business hours. To order or get more vacation package details, please visit

For more information on Provista’s parent company, Todos Medical, please visit For more information on Provista Diagnostics’ CLIA / CAP certified lab, please visit

About Todos Medical Ltd.
Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs vital diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S. medical diagnostics company Provista Diagnostics, Inc. to secure the rights to its CLIA / CAP certified lab based in Alpharetta, Georgia, which currently performs COVID PCR testing and blood of Videssa® breast cancer from Provista. test. The company’s state-of-the-art and patented Todos Biochemical Infrared Analyzes (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that deploys a comprehensive examination of the influence of cancer on the immune system, at the search for biochemical changes in mononuclear cells in blood and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos is focused on commercializing Videssa and will commercialize the TBIA tests thereafter.

Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to deal with the COVID-19 pandemic. The joint venture continues to develop diagnostic assays targeting 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s exclusive therapeutic candidate, Tollovir â„¢, is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to launch phase 2/3 clinical trials for inpatients and outpatients in Israel.

Todos is also developing blood tests for the early detection of neurodegenerative diseases, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test â„¢) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant reentry of the cell cycle by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos also distributes certain (COVID-19) testing materials and supplies to CLIA certified laboratories in the United States. The products cover multiple suppliers of PCR test kits, extraction kits, automation equipment and supplies, as well as COVID-19 antibody and antigen test kits.

For more information, please visit

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our clinical development programs and expected clinical trials. These forward-looking statements are based solely on management’s current expectations, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements, including risks and uncertainties associated with progress, timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to secure the additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in forward-looking statements: changes in technology and market requirements; delays or obstacles in starting our clinical trials; changes in legislation; the inability to develop and introduce new technologies, products and applications in a timely manner; the lack of validation of our technology as we progress and the lack of acceptance of our methods by the scientific community; failure to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; a higher cost of the final product than expected; loss of market share and price pressure resulting from competition; and laboratory results which do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated in such forward-looking statements. Unless otherwise required by law, Todos Medical undertakes no obligation to publish revisions of these forward-looking statements to reflect events or circumstances subsequent to the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the United States Securities and Exchange Commission.

Contact Companies and Investors:
Richard galterio
To do Medical
[email protected]

Previous New legal battle over predator assassination in the Nevada wilderness | Nevada News
Next Laboratory Co. of America Holdings (NYSE: LH) Director Dwight Gary Gilliland sells 500 shares